{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not calculated due to insufficient number of events","groupId":"OG000","lowerLimit":"168.0","upperLimit":"NA","value":"268.3"},{"comment":"Upper limit not calculated due to insufficient number of events","groupId":"OG001","lowerLimit":"183.7","upperLimit":"NA","value":"306.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"description":"DOR is from initial response (at least CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change. Analysis was based on Kaplan Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG000","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG001","title":"Arm B: Rituximab"}],"paramType":"MEDIAN","populationDescription":"The analysis is only performed for participants who have achieved PR or better after the first dose date of maintenance therapy and prior to any treatment change.\n\nArm B includes 3 additional participants who achieved CR/CRu/PR in the follow-up period.","reportingStatus":"POSTED","timeFrame":"From the initial response (at least PR) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death, whichever occurs first (up to approximately 432 weeks)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Weeks"}